Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 19 September 2017

Verona Pharma plc : Miscellaneous

Verona Pharma plc    

Published: 13:46 CEST 19-09-2017 /GlobeNewswire /Source: Verona Pharma plc / : VRP /ISIN: GB00BYW2KH80

Verona Pharma plc : Miscellaneous


Issue of Shares


September 19, 2017, London - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will issue 133,333 new ordinary shares in the capital of the Company (the "New Shares") following an exercise of share options by N+1 Singer Capital Markets Limited. Application has been made to the London Stock Exchange for the New Shares to be admitted to trading on AIM, with dealings expected to commence on 22 September 2017 ("Admission").


Following Admission, the Company will have a total of 105,017,401 Ordinary Shares in issue each carrying one voting right. The Company does not hold any Ordinary Shares in Treasury. This figure of 105,017,401 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.


About Verona Pharma plc


Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.


For further information, please contact:

Verona Pharma plc

Tel: +44 (0)20 3283 4200

Jan-Anders Karlsson, Chief Executive Officer




Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)

Tel: +44 (0) 20 7710 7600


Stewart Wallace / Jonathan Senior / Ben Maddison


This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Verona Pharma plc, 3 More London Riverside, London SE1 2RE, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.